X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NOVARTIS - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NOVARTIS FRESENIUS KABI ONCO./
NOVARTIS
 
P/E (TTM) x 22.1 360.9 6.1% View Chart
P/BV x 3.1 31.8 9.8% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 FRESENIUS KABI ONCO.   NOVARTIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NOVARTIS
Mar-18
FRESENIUS KABI ONCO./
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs176758 23.2%   
Low Rs79579 13.6%   
Sales per share (Unadj.) Rs37.7228.4 16.5%  
Earnings per share (Unadj.) Rs5.131.7 16.0%  
Cash flow per share (Unadj.) Rs6.732.8 20.5%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs42.5297.1 14.3%  
Shares outstanding (eoy) m158.2324.69 640.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 115.4%   
Avg P/E ratio x25.021.1 118.6%  
P/CF ratio (eoy) x18.920.4 92.8%  
Price / Book Value ratio x3.02.2 132.9%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m20,13516,505 122.0%   
No. of employees `0001.20.7 172.5%   
Total wages/salary Rs m7031,445 48.7%   
Avg. sales/employee Rs Th5,176.28,441.3 61.3%   
Avg. wages/employee Rs Th610.42,163.6 28.2%   
Avg. net profit/employee Rs Th699.61,173.1 59.6%   
INCOME DATA
Net Sales Rs m5,9635,639 105.7%  
Other income Rs m181,718 1.0%   
Total revenues Rs m5,9817,357 81.3%   
Gross profit Rs m1,430-63 -2,288.2%  
Depreciation Rs m25825 1,019.4%   
Interest Rs m-2655 -47.0%   
Profit before tax Rs m1,2161,575 77.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342792 43.2%   
Profit after tax Rs m806784 102.8%  
Gross profit margin %24.0-1.1 -2,163.8%  
Effective tax rate %28.150.3 56.0%   
Net profit margin %13.513.9 97.3%  
BALANCE SHEET DATA
Current assets Rs m5,1029,522 53.6%   
Current liabilities Rs m2,3853,296 72.4%   
Net working cap to sales %45.6110.4 41.3%  
Current ratio x2.12.9 74.0%  
Inventory Days Days15037 409.8%  
Debtors Days Days11328 398.6%  
Net fixed assets Rs m5,14846 11,191.5%   
Share capital Rs m158123 128.2%   
"Free" reserves Rs m6,5567,213 90.9%   
Net worth Rs m6,7327,336 91.8%   
Long term debt Rs m9520-   
Total assets Rs m10,38811,105 93.5%  
Interest coverage x-45.829.5 -155.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.5 113.1%   
Return on assets %7.57.6 99.4%  
Return on equity %12.010.7 112.1%  
Return on capital %14.622.2 65.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29861 8,741.9%   
Fx outflow Rs m1,7723,630 48.8%   
Net fx Rs m3,525-3,570 -98.8%   
CASH FLOW
From Operations Rs m1,2741,610 79.1%  
From Investments Rs m-1,204687 -175.3%  
From Financial Activity Rs m-196-2,677 7.3%  
Net Cashflow Rs m-126-380 33.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 9.6 1.6 600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   42,599 41,647 102.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STERLING BIOTECH  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA LTD  GSK PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 260 Points Down; TCS & Infosys Top Losers(12:30 pm)

Stock markets in India are presently trading lower, tracking weakness in their global peers. Among the sectoral indices, IT stocks and metal stocks are witnessing maximum selling pressure.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS